Recommendations for routine testing and follow-up for chronic hepatitis B virus (HBV) infection by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis.
                             
                     
        
 
       
       
     
 
             





         
                   
   
     
     
      
             
                
 
         
                   
   
  
      
      
Recommendations for Routine Testing and Follow-up
 
for Chronic Hepatitis B Virus (HBV) Infection 

Recommendation 
Population Testing Vaccination/Follow-up 
Persons born in regions of high and 
intermediate HBV endemicity (HBsAg 
prevalence 2%) 
Test for HBsAg, regardless of vaccination status 
in their country of origin, including 
– immigrants 
– refugees 
– asylum seekers 
– internationally adopted children 
If HBsAg-positive, refer for medical management. 
If negative, assess for on-going risk for hepatitis B and 
vaccinate if indicated. 
US born persons not vaccinated as 
infants whose parents were born in 
regions with high HBV endemicity ( 8%) 
Test for HBsAg regardless of maternal HBsAg 
status if not vaccinated as infants in the 
United States. 
If HBsAg-positive, refer for medical management. 
If negative, assess for on-going risk for hepatitis B and 
vaccinate if indicated. 
Continues on back 
Geographic Distribution of Chronic HBV Infection — Worldwide, 2006* 
HBsAg prevalence 
8% = high 
2%–7% = intermediate 
<2% = low 
* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data and might not reflect current 
prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might vary within countries by subpopulation and locality. 
Source: CDC. Travellers’ Health; Yellow Book.  http://wwwn.cdc.gov/travel/yellowbookch4-HepB.aspx. 
 
Routine Testing and Follow-up for Chronic HBV Infection (continued)
 
Recommendation 
Population Testing Vaccination/Follow-up 
Injection-drug users                   Test for HBsAg, as well as for anti-HBc or 
       anti-HBs to identify susceptible persons. 
                     First vaccine dose should be given at the same visit as testing. 
               Susceptible persons should complete a 3-dose hepatitis B 
             vaccine series to prevent infection from ongoing exposure. 
Men who have sex with men                   Test for HBsAg, as well as for anti-HBc or 
       anti-HBs to identify susceptible persons. 
                     First vaccine dose should be given at the same visit as testing. 
               Susceptible persons should complete a 3-dose hepatitis B 
             vaccine series to prevent infection from ongoing exposure. 
Persons needing immunosuppressive 
 therapy, including chemotherapy,
immunosuppression related 
to organ transplantation, and 
immunosuppression for rheumatologic 
or gastroenterologic disorders 
               Test for all markers of HBV infection (HBsAg, 
   anti-HBc, and anti-HBs). 
         Treat persons who are HBsAg-positive. 
                   Monitor closely persons who are anti-HBc positive for signs of 
    liver disease. 
Persons with elevated ALT/AST of 
unknown etiology 
             Test for HBsAg along with other appropriate  
 medical evaluation. 
      Follow-up as indicated. 
 Donors of blood, plasma, organs,
tissues, or semen 
           Test for HBsAg, anti-HBc, and HBV-DNA  
 as required. 
Hemodialysis patients                Test for all markers of HBV infection (HBsAg, 
   anti-HBc, and anti-HBs). 
           Test vaccine nonresponders monthly for HBsAg. 
         HBsAg-positive hemodialysis patients should be 
cohorted. 
               Vaccinate against hepatitis B to prevent transmission and 
             revaccinate when serum anti-HBs titer falls below 10mIU/mL. 
All pregnant women            Test for HBsAg during each pregnancy, 
       preferably in the first trimester. 
                 Test at the time of admission for delivery if 
                 prenatal HBsAg test result is not available or if 
             mother was at risk for infection during pregnancy. 
         If HBsAg-positive, refer for medical management. 
             To prevent perinatal transmission, infants of HBsAg-positive 
               mothers and unknown HBsAg status mothers should receive 
           vaccination and postexposure immunoprophylaxis in accordance 
             with recommendations and within 12 hours of delivery. 
    Infants born to HBsAg-positive mothers                Test for HBsAg and anti-HBs 1–2 mos after 
                 completion of at least 3 doses of a licensed 
               hepatitis B vaccine series (i.e., at age 9–18 
             months, generally at the next well-child visit 
         to assess effectiveness of postexposure 
         immunoprophylaxis). Testing should not be 
               performed before age 9 months or within 1 
           month of the most recent vaccine dose. 
       Vaccinate in accordance with recommendations. 
Household, needle-sharing, or sex 
contacts of persons known to be 
HBsAg positive 
                 Test for HBsAg, as well as anti-HBc or anti-HBs 
     to identify susceptible persons. 
                     First vaccine dose should be given at the same visit as testing. 
               Susceptible persons should complete a 3-dose hepatitis B 
             vaccine series to prevent transmission from ongoing exposure. 
      Persons who are the sources of blood 
      or body fluids resulting in an exposure 
    (e.g., needlestick, sexual assault) that 
   might require postexposure prophylaxis 
     Test source for HBsAg.              Vaccinate healthcare and public safety workers with 
             reasonably anticipated occupational exposures to blood or 
     infectious body fluids. 
             Provide postexposure prophylaxis to exposed person if needed. 
HIV-positive persons                   Test for HBsAg, as well as for anti-HBc or 
       anti-HBs to identify susceptible persons. 
               Vaccinate susceptible persons against hepatitis B to prevent 
 transmission. 
                        
      
Adapted from: Centers for Disease Control and Prevention. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus 
Infection. MMWR 2008; 57 (No. RR-8). 
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